About Vermillion (NASDAQ:VRML)
Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Diagnostics & Testing
- Sub-Industry: N/A
- Symbol: NASDAQ:VRML
- CUSIP: N/A
- Web: www.vermillion.com
Capitalization:- Market Cap: $84.81 million
- Outstanding Shares: 56,164,000
Average Prices:- 50 Day Moving Avg: $1.48
- 200 Day Moving Avg: $1.64
- 52 Week Range: $0.76 - $2.85
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.05 million
- Price / Sales: 27.44
- Book Value: $0.08 per share
- Price / Book: 18.63
Profitability:- EBITDA: ($10,500,000.00)
- Net Margins: -372.05%
- Return on Equity: -215.26%
- Return on Assets: -121.77%
Debt:- Debt-to-Equity Ratio: 0.34%
- Current Ratio: 3.21%
- Quick Ratio: 3.16%
Misc:- Average Volume: 52,466 shs.
- Beta: 2.52
- Short Ratio: 16.56
Frequently Asked Questions for Vermillion (NASDAQ:VRML)
What is Vermillion's stock symbol?
Vermillion trades on the NASDAQ under the ticker symbol "VRML."
How were Vermillion's earnings last quarter?
Vermillion, Inc. (NASDAQ:VRML) announced its earnings results on Wednesday, August, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The firm had revenue of $0.90 million for the quarter. Vermillion had a negative net margin of 372.05% and a negative return on equity of 215.26%. View Vermillion's Earnings History.
Where is Vermillion's stock going? Where will Vermillion's stock price be in 2017?
1 equities research analysts have issued twelve-month price objectives for Vermillion's stock. Their predictions range from $1.75 to $1.75. On average, they expect Vermillion's share price to reach $1.75 in the next twelve months. View Analyst Ratings for Vermillion.
Are investors shorting Vermillion?
Vermillion saw a increase in short interest in September. As of September 15th, there was short interest totalling 982,035 shares, an increase of 27.9% from the August 31st total of 767,768 shares. Based on an average daily volume of 43,840 shares, the short-interest ratio is presently 22.4 days. Approximately 3.1% of the company's stock are short sold.
Who are some of Vermillion's key competitors?
Some companies that are related to Vermillion include Viralytics (VRACY), Cytosorbents Corporation (CTSO), Summit Therapeutics PLC (SMMT), Adamis Pharmaceuticals Corporation (ADMP), Ocular Therapeutix (OCUL), Vascular Biogenics (VBLT), Marinus Pharmaceuticals (MRNS), ConforMIS (CFMS), Advaxis (ADXS), CASI Pharmaceuticals (CASI), Concord Medical Services Holdings Limited (CCM), Genesis Healthcare (GEN), BioDelivery Sciences International (BDSI), Osiris Therapeutics (OSIR), Adocia (ADOCY), Majesco Entertainment Company (COOL), Cempra (CEMP) and Dimension Therapeutics (DMTX).
Who are Vermillion's key executives?
Vermillion's management team includes the folowing people:
- James T. LaFrance, Chairman of the Board
- Valerie Barber Palmieri, President, Chief Executive Officer
- Fred Ferrara, Chief Operating Officer
- Donald G. Munroe Ph.D., Senior Vice President - Business Development, Chief Scientific Officer
- Eric J. Schoen, Chief Accounting Officer, Vice President - Finance
- James S. Burns, Independent Director
- Veronica G. H. Jordan Ph.D., Independent Director
- David R Schreiber, Independent Director
- Carl Severinghaus, Independent Director
- Eric K. Varma M.D., Independent Director
How do I buy Vermillion stock?
Shares of Vermillion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vermillion's stock price today?
One share of Vermillion stock can currently be purchased for approximately $1.49.
MarketBeat Community Rating for Vermillion (NASDAQ VRML)MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Vermillion (NASDAQ:VRML) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $1.75 (17.45% upside) |
Consensus Price Target History for Vermillion (NASDAQ:VRML)
Analysts' Ratings History for Vermillion (NASDAQ:VRML)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/30/2017 | Canaccord Genuity | Reiterated Rating | Buy | $2.50 -> $1.75 | Low |  |
(Data available from 10/21/2015 forward)
Earnings History for Vermillion (NASDAQ:VRML)Earnings History by Quarter for Vermillion (NASDAQ VRML)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/9/2017 | Q2 2017 | ($0.04) | ($0.04) | | $0.90 million | View | Listen | |
| 5/18/2017 | Q1 2017 | ($0.04) | ($0.05) | | $0.73 million | View | N/A | |
| 11/10/2016 | Q316 | ($0.06) | ($0.07) | | $0.62 million | View | N/A | |
| 8/10/2016 | Q216 | ($0.09) | ($0.07) | | $0.71 million | View | Listen | |
| 5/16/2016 | Q116 | ($0.09) | ($0.09) | | $0.51 million | View | Listen | |
| 3/24/2016 | Q415 | | ($0.10) | $1.20 million | $0.36 million | View | Listen | |
| 11/12/2015 | Q315 | ($0.10) | ($0.10) | $0.57 million | $0.33 million | View | Listen | |
| 8/13/2015 | Q215 | ($0.08) | ($0.11) | $1.50 million | $535.00 million | View | Listen | |
| 5/11/2015 | Q115 | ($0.10) | ($0.10) | $0.81 million | $0.95 million | View | Listen | |
| 3/25/2015 | Q414 | ($0.08) | ($0.11) | $1.59 million | $1.57 million | View | Listen | |
| 11/14/2013 | Q3 | | ($0.10) | $319.00 million | $330.00 million | View | Listen | |
| 8/14/2013 | Q2 2013 | | ($0.11) | $0.32 million | $0.23 million | View | Listen | |
| 5/15/2013 | Q1 2013 | ($0.15) | ($0.17) | $0.30 million | $0.33 million | View | Listen | |
| 11/12/2012 | Q312 | ($0.21) | ($0.13) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Vermillion (NASDAQ:VRML)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Vermillion (NASDAQ:VRML)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vermillion (NASDAQ:VRML)Insider Ownership Percentage: 3.67%
Institutional Ownership Percentage: 35.57%
Insider Trades by Quarter for Vermillion (NASDAQ:VRML)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/16/2017 | Valerie Barber Palmieri | Insider | Buy | 694 | $1.44 | $999.36 | |
| 9/15/2017 | Valerie Barber Palmieri | Insider | Buy | 719 | $1.39 | $999.41 | |
| 8/23/2017 | Valerie Barber Palmieri | Insider | Buy | 768 | $1.30 | $998.40 | |
| 5/17/2017 | Valerie Barber Palmieri | Insider | Buy | 555 | $1.80 | $999.00 | |
| 2/17/2017 | Larry N Feinberg | Insider | Buy | 617,731 | $1.40 | $864,823.40 | |
| 2/13/2017 | Eric Schoen | SVP | Buy | 3,347 | $1.40 | $4,685.80 | |
| 2/13/2017 | Jack W Schuler | Major Shareholder | Buy | 974,081 | $1.40 | $1,363,713.40 | |
| 2/13/2017 | Valerie Barber Palmieri | CEO | Buy | 10,042 | $1.40 | $14,058.80 | |
| 2/13/2017 | Veronica Gh Jordan | Director | Buy | 6,695 | $1.40 | $9,373.00 | |
| 1/28/2016 | Jack W Schuler | Major Shareholder | Buy | 1,493 | $1.60 | $2,388.80 | |
| 1/25/2016 | Jack W Schuler | Major Shareholder | Buy | 3,700 | $1.57 | $5,809.00 | |
| 1/21/2016 | Jack W Schuler | Major Shareholder | Buy | 30,700 | $1.46 | $44,822.00 | |
| 1/19/2016 | Jack W Schuler | Major Shareholder | Buy | 57,749 | $1.45 | $83,736.05 | |
| 1/15/2016 | Jack W Schuler | Major Shareholder | Buy | 8,400 | $1.56 | $13,104.00 | |
| 7/14/2015 | Larry N Feinberg | Insider | Buy | 512,043 | $1.96 | $1,003,604.28 | |
| 12/23/2014 | Jack W Schuler | Major Shareholder | Buy | 1,288,339 | $1.44 | $1,855,208.16 | |
| 12/23/2014 | Larry N Feinberg | Insider | Buy | 972,222 | $1.44 | $1,399,999.68 | |
| 12/19/2014 | Peter S Roddy | Director | Buy | 16,502 | $1.44 | $23,762.88 | |
| 11/21/2014 | Valerie Barber Palmieri | COO | Buy | 3,500 | $1.51 | $5,285.00 | |
| 11/20/2014 | James T Lafrance | Insider | Buy | 27,907 | $1.44 | $40,186.08 | |
| 11/20/2014 | Valerie Barber Palmieri | COO | Buy | 30,000 | $1.44 | $43,200.00 | |
| 11/19/2014 | James T Lafrance | Insider | Buy | 41,615 | $1.43 | $59,509.45 | |
| 11/18/2014 | Eric Schoen | CAO | Buy | 5,000 | $1.42 | $7,100.00 | |
| 11/20/2013 | William B Creech | VP | Buy | 2,000 | $2.33 | $4,660.00 | |
| 6/11/2013 | William B Creech | VP | Buy | 10,000 | $3.18 | $31,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Vermillion (NASDAQ:VRML)
Latest Headlines for Vermillion (NASDAQ:VRML)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Vermillion, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 2:40 PM |
| ASPiRA Labs Announces In-Network Contract Agreement with HealthNet Federal Services for OVA1®
finance.yahoo.com - October 3 at 2:40 PM |
 | Vermillion, Inc. (VRML) Sees Significant Increase in Short Interest
www.americanbankingnews.com - September 30 at 3:50 AM |
| Is It Too Late To Buy Vermillion Inc (VRML)?
finance.yahoo.com - September 23 at 10:49 AM |
| ETFs with exposure to Vermillion, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 8:30 PM |
| Vermillion, Inc. :VRML-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 9:22 AM |
| Vermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell
finance.yahoo.com - September 1 at 10:56 AM |
| Vermillion, Inc. (VRML) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - August 30 at 4:56 PM |
| Critical Analysis: Vermillion (VRML) & CareDx (CDNA)
www.americanbankingnews.com - August 25 at 2:12 PM |
| CareDx (CDNA) vs. Vermillion (VRML) Critical Comparison
www.americanbankingnews.com - August 18 at 10:46 AM |
| Edited Transcript of VRML earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 13 at 7:34 AM |
| Vermillion, Inc. (VRML) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - August 10 at 6:21 PM |
| Vermillion Reports Second Quarter 2017 Results
finance.yahoo.com - August 10 at 9:32 AM |
| Vermillion Announces Date Change of Second Quarter 2017 Financial Results and Investor Conference Call
finance.yahoo.com - August 5 at 8:22 AM |
| Vermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th
finance.yahoo.com - August 2 at 8:35 AM |
| Financial Survey: Veracyte (VCYT) and Vermillion (NASDAQ:VRML)
www.americanbankingnews.com - August 1 at 8:46 AM |
| Analyzing Veracyte (VCYT) & Vermillion (VRML)
www.americanbankingnews.com - July 31 at 2:23 PM |
| Vermillion to Report Second Quarter 2017 Financial Results and Host Investor Conference Call on August 8th
finance.yahoo.com - July 28 at 9:47 AM |
| Vermillion (NASDAQ:VRML) vs. InVitae Corp (NVTA) Head-To-Head Survey
www.americanbankingnews.com - July 24 at 2:14 PM |
| Vermillion (VRML) vs. Lion Biotechnologies (IOVA) Head-To-Head Comparison
www.americanbankingnews.com - July 20 at 6:27 PM |
| Vermillion, Inc. (NASDAQ:VRML) Receives Average Recommendation of "" from Analysts
www.americanbankingnews.com - July 17 at 8:14 PM |
| Critical Survey: Vermillion (VRML) vs. InVitae Corp (NVTA)
www.americanbankingnews.com - July 14 at 12:08 AM |
| ETFs with exposure to Vermillion, Inc. : July 11, 2017
finance.yahoo.com - July 12 at 9:05 AM |
| Affymetrix (AFFX) versus Vermillion (VRML) Critical Contrast
www.americanbankingnews.com - July 1 at 10:04 PM |
 | After raising $2 million, Austin's Consortia Health tackles problems that might make some blush
www.bizjournals.com - April 15 at 7:00 PM |
| VERMILLION, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - April 1 at 9:38 AM |
| Q4 2016 Vermillion Inc Earnings Release - Before Market Open
biz.yahoo.com - March 29 at 10:17 AM |
| VERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - March 13 at 8:09 PM |
| VERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 4 at 3:56 AM |
| ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1®
www.bizjournals.com - March 2 at 1:23 AM |
| VERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
biz.yahoo.com - February 17 at 5:05 PM |
 | Vermillion Announces Equity Financing of $5.6 Million
us.rd.yahoo.com - February 14 at 3:49 PM |
| VERMILLION, INC. Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 9 at 3:53 PM |
| VERMILLION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 7 at 6:22 AM |
| 4:06 pm Vermillion & ASPiRA LABS announce receipt of formal FDA clarification regarding ovarian cancer screening alert
us.rd.yahoo.com - January 6 at 6:31 AM |
 | Vermillion's (VRML) CEO Valerie Palmieri on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 11 at 8:01 PM |
| Q3 2016 Vermillion Inc Earnings Release - After Market Close
biz.yahoo.com - November 10 at 11:58 AM |
| VERMILLION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - August 10 at 11:25 AM |
| VERMILLION, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - June 22 at 4:07 PM |
Vermillion (VRML) Chart for Saturday, October, 21, 2017
